PF-07321332, also known as Paxlovid, is an orally bioavailable 3C-like protease (3CLPRO) inhibitor. This drug is being investigated for safety, tolerability, and pharmacokinetics before moving on to studies of efficacy in the treatment or prophylaxis of COVID-19. 3CLPRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2. PF-07321332 is an oral COVID-19 antiviral clinical candidate. By inhibiting the main protease, PF-07321332 prevents the virus from cleaving long protein chains into the parts it needs to reproduce itself.
SARS-CoV Inhibitors Related Products:
Nafamostat; Nafamostat mesylate; PLpro inhibitor; PF-00835231; ML188; Molnupiravir N-1; Molnupiravir